Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

d-LIVER · ICT-enabled, cellular artificial liver system incorporating personalized patient management and support

FP7Status: CLOSED1 October 201130 September 2015EU funding €10,959,000

d-LIVER applies scenario-driven development methodologies to address an unmet need for bio-artificial liver support via continuous detoxification as remote transient therapy at the Point-of-Need. The liver is a complex organ with various vital functions in synthesis, detoxification and regulation; its failure is life-threatening and the only curative treatment is transplantation. Whilst awaiting transplantation, or after liver resection, patients need to be supported with detoxification systems which, currently mainly based on filtration, do not support metabolic liver function. This can only be provided by living cells. Thus, development of ICT-enabled bio-artificial liver support systems with associated remote monitoring to assist in the treatment and management of liver patients in care settings extending from the hospital to the home is essential.d-LIVER targets sensor-based monitoring of patient health status at home, concentrating on continuous monitoring of physiological parameters and discrete measurement of a defined set of biochemical species. d-LIVER also targets remote monitoring and control of the bio-artificial liver and communication with patient sensor networks and hospital information systems. Systems will be capable of remote, secure communication of the status of both the patient and the bio-artificial liver to central clinical services such that they can schedule swift and beneficial treatment and remedial actions. In this way d-LIVER will provide fundamental advances in liver support by reducing hospitalisation costs while enhancing quality of care and, at the same time, reinforcing European leadership in Personal Health systems.In a parallel, high-risk, activity the production of human hepatocytes from pancreatic progenitor cells will be investigated. These would be ideal for use in d-LIVER systems since they may provide an unlimited supply of hepatocytes, which would overcome drawbacks associated with both primary hepatocytes and stem cells.

Consortium · 15 organisations

coordinator

UNIVERSITY OF NEWCASTLE UPON TYNE

UK · €1,537,149

participant

STIFTELSEN SINTEF

NO · €1,434,274

participant

UNIVERSITAT ROVIRA I VIRGILI

ES · €836,266

participant

STAR HEALTHCARE MANAGEMENT GMBH

DE · €299,700

participant

STEM CELL SYSTEMS GMBH

DE · €201,900

participant

DEKRA TESTING AND CERTIFICATION SAU

ES · €282,350

participant

CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT

CH · €998,209

participant

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV

DE · €1,934,086

participant

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

FR · €1,166,597

participant

IXSCIENT LIMITED

UK · €419,960

participant

Olivetti I-Jet

IT · €27,800

participant

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

DE · €1,100,996

participant

HUMANITAS MIRASOLE SPA

IT · €36,000

participant

enablingMNT GMBH

DE · €234,300

participant

INSTITUT FUER MIKROTECHNIK MAINZ GMBH

DE · €449,413

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.